Magle Chemoswed congratulates Oncopeptides

27/02/2021

Magle Chemoswed congratulates everyone at Oncopeptides for receiving FDA approval of PEPAXTO®. We are proud to have been chosen by Oncopeptides as a development and manufacturing partner for the active pharmaceutical substance. It has been a great pleasure to support Oncopeptides and supply development and manufacturing services around the active pharmaceutical substance through all phases of the development and clinical stages.

“Working with Oncopeptides as a partner in development and manufacturing has been a real honour, and we look forward to further supporting Oncopeptides in the commercial supply of their active pharmaceutical substance in the future, “ said Fredrik Andersson, Chief Operating Officer of Magle Chemoswed.

Contacts

Justin Pierce, CEO, phone +46 (0)70 593 58 21, justin.pierce@maglegroup.com

About Us

Magle Chemoswed is a unique international contract development manufacturing company dedicated to bringing ideas to product for customers alongside building our own product pipeline based on our patented technology base. As an integrated company, we have extensive capabilities across the value chain, from the discovery, development and manufacture of medicines and medical devices that rely on our patented and trade secret protected technology platform.

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Attachments

Magle Chemoswed congratulates Oncopeptides